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Background: Genetic transformation of skeletal myoblasts for myocardial
repair is dependent on an efficient gene transfer system that integrates the
genes of interest into the genome of the target cell and its progeny. The aim
of this investigation was to evaluate the use of a new retrovirally based gene
transfer system for this purpose. Methods: MFGnlslacZ retroviral vector,
packaged in high-titer, split-genome packaging cell line (FLYA4) was used
to transduce the skeletal myoblast cell line L6. L6 cells, cultured in 10%
fetal calf serum, were transduced with the MFGnlslacZ vector by means of
filtered supernatant from FLYA4 cells. Transduced L6 cells were divided
into four groups. Group I cells were fixed as myoblasts 3 days after
transduction. Group II cells were allowed to differentiate into myotubes.
Group III cells were split every 3 days for 4 months. Group IV cells were
split as in group III but then allowed to differentiate into myotubes. All
samples were fixed and stained for b-galactosidase activity. The effects on
gene transfer of transforming growth factor–b, insulin-like growth factor–I,
and platelet-derived growth factor were determined by spectrophotometric
assay of b-galactosidase activity in cells transduced in the presence or
absence of serum with 0 to 200 ng/ml of each growth factor. Results:
Morphometric analysis showed that 66.3% 6 3% to 69.6% 6 6% of cells in
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groups I to IV expressed the lacZ reporter gene. In the presence of serum,
transforming growth factor–b significantly inhibited gene transfer, whereas
insulin-like growth factor–I and platelet-derived growth factor significantly
enhanced gene transfer. In absence of serum, however, only platelet-derived
growth factor enhanced retrovirally mediated gene transfer into skeletal
myoblasts. Conclusion: MFG retroviral vectors packaged in FLYA4 cells are
efficient in gene transfer into skeletal myoblasts and result in transgenic
expression that is maintained after repeated cell division, differentiation, or
both. Platelet-derived growth factor enhances retrovirally mediated gene
transfer into skeletal myoblasts. (J Thorac Cardiovasc Surg 1998;115:1-8)
Genetic transformation of skeletal myoblasts is animportant aim of gene transfer, not only for the
treatment of skeletal myopathies1 but also for myo-
cardial repair.2, 3 Two main experimental ap-
proaches have been adopted for myocardial repair
by skeletal muscle cells: direct injection of skeletal
myoblasts into the heart2, 3 and transformation of
fibroblasts into skeletal muscle cells by means of the
myogenic basic-helix–loop-helix transcription factor
MyoD.4 Skeletal muscle cells, however, lack essen-
tial cardiac-specific proteins, such as gap-junction
proteins, that allow direct intercellular communica-
tion and act as low-resistance pathways for the
propagation of action potential in myocardium.5 We
are currently exploring the possibility of genetically
transforming skeletal myoblasts to express the gap-
junction protein (connexin 43). The success of this
approach is dependent on establishing a gene-trans-
fer system that allows permanent integration of the
“therapeutic” gene into the chromosome of the
target cells and their progeny.
Unlike adenoviral vectors, both adeno-associated
and retroviral vectors integrate into the chromo-
some.6, 7 We chose a retroviral vector for these
studies because their biology is well known and they
have been in use in clinical gene therapy since 1989
without serious side effects.6 Most of these clinical
protocols use vectors that are based on the Moloney
Murine Leukemia Virus (MoMuLV), which is ren-
dered replication-defective by deletion of sequences
coding for essential proteins required for the pack-
aging of the viral particles.6, 8 The gene of interest is
then cloned into this vector, and the resulting con-
struct is reproduced in cells containing the genes
required for viral packaging.9 Such vectors have
been used to carry a dystrophin minigene into
skeletal myoblasts in vitro and in vivo, with an
efficiency of 5% to 10%.10, 11 The low rate of gene
transfer in these studies has been attributed to
inadequate viral titer, poor packaging efficiency, and
the instability of the vectors produced.
The MFG retroviral vector, which is based on the
MoMuLV, has been engineered to allow efficient
translation and packaging of recombinant vec-
tors.8, 12 Furthermore, retroviral packaging cell lines
such as FLYA4 produce high-titer retroviral vectors
that are more stable than previous vectors.13 One
limitation of retrovirally mediated gene transfer is
the need for the target cells to be actively dividing
to allow gene integration.4 To circumvent this limi-
tation, growth factors have been used to enhance
retrovirally mediated gene transfer into
hematopoietic stem cells.15 In this study, we in-
vestigated the efficiency of the MFG retroviral vec-
tor, packaged in FLYA4 cells, in gene transfer into
the rat skeletal myoblast cell line L6. We also tested
the effects of the growth factors insulin-like growth
factor–I (IGFI), transforming growth factor–b
(TGF-b), and platelet-derived growth factor (PDGF)
on gene transfer.
Materials and methods
Cells lines and media. The MFG vector has previously
been engineered to carry the lacZ reporter gene, which
encodes the bacterial enzyme b-galactosidase with a nu-
clear localization signal (nls).8, 12 The vector was packaged
in FLYA4 cells13 (gift from Professor Weiss, Chester
Beatty Laboratories, Institute for Cancer Research, Lon-
don). This cell line was derived from the human fibrosar-
coma HT1080 cells (American Type Culture Collection,
Rockville, Md.) and has been genetically engineered to
express the gag-pol and the env genes on two separate
transcription units.13 The number of infectious units pro-
duced was determined by transducing NIH 3T3 murine
fibroblast cell line (American Type Culture Collection) in
a serial titration. The skeletal myoblast cell line L6
(American Type Culture Collection) provided target cells
for gene transfer. The cells were maintained in 75 cm2
filter flasks containing Dulbecco’s modified Eagle’s me-
dium (Sigma, Poole, United Kingdom) supplemented
with 2 mmol/L glutamine, 50 mmol/ml penicillin, 50
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mmol/ml streptomycin, and 10% fetal calf serum (FCS).
Serum-free medium consisted of OPTIMEM 1 (Sigma)
supplemented with 50 mmol/ml penicillin and 50 mmol/ml
streptomycin. All cells were incubated at 37° C in a
humidified chamber equilibrated with 5% (volume/vol-
ume) carbon dioxide in air.
Gene transfer into skeletal myoblasts and determina-
tion of MFG transduction efficiency. To determine the
ideal concentration of viral vectors in transducing skel-
etal myoblasts, L6 cells were plated in 6-well multiwell
plates at a density of 1 3 105 cells/well. At 60%
confluence, cells were transduced by adding 4 ml me-
dium containing either 106, 105, 104, 103, or 10 infec-
tious units and reincubated for 3 days. The cells were
then fixed and stained for b-galactosidase activity and
subjected to morphometric analysis. We then estimated
the biologic transduction efficiency (BTE) of the MFG
vector, as described by Tavoloni16 and summarized in
Fig. 1. In these and the following experiments, we used
106 infectious units/ml. The target cells were exposed to
only one dose of viral supernatant for 3 days unless
otherwise indicated.
Another group of L6 cells was cultured in 25 cm2 tissue
culture flasks, at a density of 1 3 106 cells/flask, and
incubated as outlined previously. At 60% confluency, L6
cells were transduced by adding MFGnlslacZ to the
concentration of 106 infectious units/ml. Transduced L6
cells were then divided into the following four groups:
Group I: Cells were fixed as myoblasts 3 days after
transduction and were then stained.
Group II: Cells were allowed to differentiate into myo-
tubes by reducing serum concentration to 2% for 7 days
and were then fixed and stained.
Group III: Cells were split by trypsinization every 3 days
(1:4), thereby maintaining them as dividing myoblasts,
for 4 months and were then fixed and stained.
Group IV: Cells were split as in group III but allowed to
Fig. 1. Estimation of BTE of the MFG vector. Schematic representation of protocol used to study the
vector. L6 myoblasts were split in 12-well multiwell plates at a density of 0.5 3 105 cells per well. At 60%
confluence, cells were transduced by adding 1 ml medium containing 106 infectious units of MFGnlasLacZ.
At time 0 (TE0), the medium in well number 1 was replaced with 1 ml viral supernatant to allow adsorption
of vector to the L6 cells. After 1 hour of incubation at 37° C, the medium from well number 1 was
completely aspirated and transferred to well number 2 (TEl) for 1 hour. This procedure was repeated every
hour for wells 3 to 6. At time 0, 30 ml viral supernatant was incubated at 37° C in a 50 ml Falcon tube. From
this stock, after the first hour, 1 ml viral supernatant was added to well number 7 for 1 hour then replaced
with the appropriate medium. The same procedure was repeated hourly for wells 8 to 11. After exposure
to the virus, the cells were maintained in 10% FCS or serum-free medium for 48 hours. The cells were then
fixed and stained for b-galactosidase activity. The number of cells successfully transduced with lacZ was
determined by morphometric analysis. BTE was determined from the formula BTE 5 TE0/(TE0 – TE1).
To determine the influence of serum withdrawal on gene transfer, we calculated BTE with the formula
BTE 5 TE0A/(TE0A – TEB), where TE0A and TE0B are the transduction efficiencies measured without
previous adsorption in 10% FCS (first hour) and without adsorption in serum-free medium (first hour),
respectively.
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differentiate into myotubes in medium containing 2%
FCS and were then fixed and stained.
For each group, untransduced L6 cells were used as a
control.
Staining for b-galactosidase activity and morphometric
analysis. After fixation in 3.7% formaldehyde for 1 hour,
L6 cells were washed and stained for b-galactosidase
activity by adding 1 ml of X-Gal staining solution (Sigma)
for 2 to 6 hours at 37° C. For morphometric analysis, each
flask was overlaid by a transparent grid consisting of
squares 1 3 1 mm, and each 1 mm square in the field of
view was placed in register with the square grid of an
eyepiece graticule of a light microscope (Zeiss, 25FL,
Welwyn Garden City, United Kingdom) that contained
121 intersections. Sampling started in the upper left part
of the section. Every fourth 1 mm square was selected for
point counting. For each selected square, the number of
intersections falling on cells with stained nuclei was re-
corded. The mean values of six readings from each sample
were recorded.
Effects of growth factors on gene transfer into skeletal
myoblasts. The L6 cells were seeded in 24-well multiwell
plates at 0.5 3 105 cells/well in 10% FCS. After 16 hours,
the medium was replaced by serum-free medium for 6
hours before addition of filtered viral supernatant con-
taining IGFI, TGF-b, or PDGF(BB) at 0 to 200 ng/ml.
Cells were then maintained in serum-free or 10% FCS-
containing medium. After 72 hours, all cells were lysed by
adding 100 ml reporter lysis buffer (Promega, Southamp-
ton, United Kingdom). b-Galactosidase activity was de-
Fig. 2. L6 skeletal myoblasts transduced with either 106, 105, 104, 103, 10, or 0 viral particles/ml (panels 1,
2, 3, 4, 5, and 6, respectively). Panel 6 is the untreated (negative) control.
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termined by incubating 10 ml cell lysate with 200 pl
Z-buffer containing o-nitrophenyl b-D-galactopyranside
(ONPG; Sigma) for 4 to 8 hours.17 The optical density
(OD) was then measured spectrophotometrically at 414
nm and corrected for total protein contents. b-Galactosi-
dase activity, expressed as OD units per microliter per
hour, was calculated according to the following formula:
OD units/ml/hr 5 A420 3 1000/~ml extract used
3 incubation time in hours!
Statistics. Data are presented as mean 6 standard
error of four samples. Student’s t test was used to compare
test samples to controls. A p value less than 0.05 was
considered significant.
Results
The number of L6 cells transduced with
MFGnlsLacZ was dependent on the number of
infectious units added to the medium (Fig. 2).
Fig. 3. Transduced L6 cells were divided into four groups. Group I cells were fixed as myoblasts 3 days
after transduction then stained (A). Group II cells were allowed to differentiate into myotubes by reducing
serum concentration to 2% for 7 days were then fixed and stained (B). Group III cells were split (1:4) every
3 days for 4 months and were then fixed and stained (C). Group IV cells were split as in group III but were
allowed to differentiate into myotubes in 2% FCS and then were fixed and stained (D).
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Transduction of 65.0% 6 6% of cells was achieved
with 1 3 106 viral particles/ml. There was no significant
gene transfer with concentrations less than 1 3 104
viral particles/ml. b-Galactosidase was not expressed
in the control groups. In groups I, II, III, and IV, the
percentages of cells expressing the transgene were
66.3% 6 3%, 69.6% 6 6%, 68.9% 6 5%, and 67.4%
6 4%, respectively (Fig. 3). There was no significant
difference in the proportion of cells expressing the
reporter gene lacZ in cells stained before and after
repeated cell division, differentiation, or both. Because
the cell-cycle duration of L6 cells is around 18 hours,
we estimate that cells in groups III and IV would have
undergone a minimum of 160 cell divisions during a
period of 4 months.
The BTE of the MFG vector, defined as the
number of infectious units present in 1 ml vector
stock solution capable of transducing L6 cells, was
76 units/ml/hr in the presence of serum and 52
units/ml/hr in the absence of serum. The rate of viral
decay varied from 5% to 23% per hour in cells
maintained in 10% FCS and from 5% to 44% per
hour in cells maintained in serum-free medium (Fig.
4). In these experiments, the cells were exposed to
the virus for 1 hour only, thus the lower transduction
efficiency compared with cells exposed for 3 days.
The maximum b-Galactosidase activities ob-
served with each growth factor in cells cultured in
10% FCS-containing or serum-free medium are
presented in Table I. In the presence of serum and
TGF-b (200 ng/ml), b-Galactosidase activity was
reduced from 7.1 6 0.7 to 2.7 6 0.1 OD units/ml/hr
(p 5 0.008). By contrast, IGFI (20 ng/ml) and PDGF
(100 ng/ml) increased b-Galactosidase activity to
10.6 6 0.4 and 11.4 6 0.8 OD units/ml/hr, respec-
tively. In absence of serum, however, the inhibitory
Fig. 4. Retroviral BTE (TE) in the presence (FCS) or absence (SFM) of serum, tested as described in Fig. 1.
Table I. Effects of growth factors on gene transfer
into skeletal myoblasts
b-Galactosidase
activity after
transduction in
10% FCS
(OD units/mg/hr)
b-Galactosidase
activity after
transduction
in SFM
(OD units/mg/hr)
Control (no growth
factors)
7.1 6 0.7 2.0 6 0.2
IGFI (20 ng/ml) 10.6 6 0.4, p 5 0.02 2.6 6 0.2, p 5 0.059
TGF-b (200 ng/ml) 2.7 6 0.1, p 5 0.008 2.2 6 0.3, p 5 0.142
PDGF (100 ng/ml) 11.4 6 0.8, p 5 0.005 4.5 6 0.3, p 5 0.039
L6 cells transduced with MFnlslacZG in presence or absence of 10% FCS
with or without IGFI, TGF-b, or PDGF(BB). b-Galactosidase activity was
assayed spectrophotometrically. Data presented as the mean value of four
experiments 6 standard error. SFM, Serum-free medium.
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effect of TGF-b and the stimulatory effect of IGFI
did not reach statistical significance. The positive
influence of PDGF on gene transfer into skeletal
myoblasts, with and without serum, were dose and
time dependent (data not shown).
Discussion
Cell transplantation is a potential therapy for
chronic myocardial disease.2, 3 Although trans-
planted neonatal cardiac myocytes can functionally
integrate with and even augment the function of the
recipient heart,18 this approach is limited by short-
age of donors and chronic graft rejection. In con-
trast, skeletal myoblasts—present in adult skeletal
muscle as satellite cells—are available in abundance
and can be grafted, successfully, into the subject’s
own heart even after manipulation ex vivo.2, 3 Func-
tional integration of these cells, however, may be
hampered by the lack of intercellular gap-junction
communication and the variations of excitation-
contraction coupling between skeletal and cardiac
myocytes.5, 19 In studies aiming at genetic transfor-
mation of skeletal muscle cells to exhibit gap junc-
tions and cardiac-type excitation-contraction cou-
pling, we assessed the use of the MFG retroviral
vector in transferring the reporter gene lacZ into
skeletal myoblasts.
We found that an MFG-based, amphotropic,
retroviral vector induces stable gene expression in
66.3% 6 3% to 69.6% 6 6% of skeletal myoblasts
and myotubes. There was no obvious deleterious
effect of genetic transformation on the growth
rate of L6 cells or on their ability to differentiate
into multinucleated myotubes. Transduced L6
cells have not been followed up for longer than 4
months. Previous in vitro studies, with earlier
generations of recombinant retroviral vectors,
showed that only 5% to 10% of skeletal myoblasts
can be transduced.10, 11 The higher rate of suc-
cessful gene transfer observed in this study may be
attributed to two main factors. First, we used a
retroviral packaging cell line that produces a high
titer of stable retroviral vectors.13 The FLYA4
packaging cell line produced 106 to 107 infectious
units/ml. The vectors produced were stable for as
long as 6 hours if used to transduce cells cultured
in 10% FCS. These findings are consistent with
those reported by Cosset and associates,13 who
found that 50% to 90% of MFGnlslacZ, packaged
in FLYA4 cells, was stable in human serum for 1
hour. Second, the use of the MFG retroviral
vector, in which a small fragment containing the 59
untranslated region of the MoMuLV envelope
gene was inserted downstream of the gag sequence
(c1) and upstream of the complementary de-
oxyribonucleic acid insertion site. These changes
result in an increase in synthesis of the spliced
ribonucleic acid, which is likely to be translated
with greater efficiency than is unspliced ribonu-
cleic because of excision of the c region.12, 20
Recent studies have shown that MFG-based vec-
tors are seven times more efficient in gene transfer
than are standard retroviral vectors.20
The BTEs of retroviral vectors are dependent on
the vector used, the cell type, and the tissue-culture
conditions.6 We observed significant reduction in
the BTE of the MFG/FLYA4 gene transfer system
on withdrawal of serum. This observation is consis-
tent with the fact that retroviral integration is de-
pendent on mitosis14 and that the lack of serum
triggers withdrawal of skeletal myoblasts from the
cell cycle. Poor retroviral transduction in the ab-
sence of FCS mirrors the low rates of in vivo
retrovirally mediated gene transfer into skeletal
muscle where only a few cells are actively divid-
ing.11, 12
Growth factors are known to enhance retrovirally
mediated gene transfer into hematopoietic stem
cells, where the use of basic fibroblast growth factor
in combination with interleukin-3, interleukin-6, and
stem-cell factor increases the BTE by 35% to 37%.15
In this study, we found PDGF(BB) and IGFI to be
significant enhancers of retrovirally mediated gene
transfer into skeletal myoblasts. In contrast, TGF-b
in high concentrations had a significant inhibitory
effect on gene transfer. The mechanism for this has
not been studied; however, PDGF and IGFI are
known to stimulate L6 proliferation.21, 22 Further-
more, TGF-b has been shown to inhibit prolifera-
tion of L6 cells.23 On the basis of this evidence only,
it seems that the effect of these growth factors on the
rate of cell division may be the main mechanism for
enhancement or retardation of gene transfer. Other
mechanisms, however, such as increased affinity of
retrovirus-specific surface receptors, may also be
involved.
In summary, recombinant retroviral vectors pack-
aged in high-titer, split-genome packaging cells are
efficient in gene transfer into skeletal myoblasts and
result in transgenic expression, which is maintained
even after repeated cell division, differentiation, or
both. PDGF enhances retrovirally mediated gene
transfer into skeletal myoblasts in the presence or
absence of serum. These findings may have impor-
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tant implications with respect to the clinical use of
genetically modified skeletal muscle cells for cardiac
assistance.
We acknowledge with thanks the advice provided by Dr.
C. Porter and Dr. Y. Takeuchi (Chester Beatty Labora-
tories, Institute for Cancer Research, London).
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Discussion
Dr. Ray C. J. Chiu (Montreal, Quebec, Canada). It’s a
nice and useful study. So far your studies have been in
vitro. Do you think your retroviral vector might express
antigenicity in vivo?
Mr. El Oakley. Retroviral vectors are not known to
express any antigenicity, but they cannot transduce
nondividing cells. So if you intend to use retroviral
vector to transform a whole adult muscle, you will not
be able to do that easily. However, if you intend to take
the skeletal satellite cells, as you’ve done in some of
your studies, you could transform the myoblasts as
myoblasts and inject them back into the diseased myo-
cardium.
Dr. King F. Kwong (St. Louis, Mo.). I have two
questions. First, regarding your vector, what is the
maximum gene insert capacity that your vector can
accommodate?
Second, connexin 43 is the principal cardiac connexin
that is already widely expressed in both the atria and
ventricle. By transfecting the heart with a connexin 43
gene construct, what do you hope to achieve?
Mr. El Oakley. The maximum gene insert capacity is
about 8 kb. What we hope to do in the future is to take
skeletal myoblast biopsy samples, isolate the satellite
cells, transduce them to express gap junctions, and then
inject these cells back into the diseased myocardium.
We hope that these cells would integrate with the
surrounding myocardium, thereby enhancing cardiac
function.
Dr. D. Glenn Pennington (Winston-Salem, N.C.). At the
most recent meeting of the International Society for Heart
and Lung Transplantation, there was some indication that
one could increase the number of cells transfected by
doing it at higher atmospheric pressure, for example, 2
atm. Have you tried that?
Mr. El Oakley. No, we haven’t tried that.
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